Zietman A - Search Results

1

Prostate specific antigen best practice statement: 2009 update.

Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Greene KL, et al. Among authors: zietman a. J Urol. 2009 Nov;182(5):2232-41. doi: 10.1016/j.juro.2009.07.093. Epub 2009 Sep 24. J Urol. 2009. PMID: 19781717

2

Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome.

Zietman AL, Coen JJ, Shipley WU, Willett CG, Efird JT. Zietman AL, et al. J Urol. 1994 Mar;151(3):640-5. doi: 10.1016/s0022-5347(17)35036-x. J Urol. 1994. PMID: 7508522

3

The effect of pelvic radiation therapy on serum levels of prostate specific antigen.

Willett CG, Zietman AL, Shipley WU, Coen JJ. Willett CG, et al. Among authors: zietman al. J Urol. 1994 Jun;151(6):1579-81. doi: 10.1016/s0022-5347(17)35306-5. J Urol. 1994. PMID: 7514692

4

Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen followup.

Zietman AL, Shipley WU, Coen JJ. Zietman AL, et al. J Urol. 1994 Nov;152(5 Pt 2):1806-12. doi: 10.1016/s0022-5347(17)32389-3. J Urol. 1994. PMID: 7523726 Review.

5

Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease.

Zietman AL, Dallow KC, McManus PA, Heney NM, Shipley WU. Zietman AL, et al. Urology. 1996 Feb;47(2):236-9. doi: 10.1016/S0090-4295(99)80423-3. Urology. 1996. PMID: 8607241 Clinical Trial.

6

Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis.

Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA, Kuban DA, Hancock SL, Smith CD. Shipley WU, et al. Among authors: zietman al. JAMA. 1999 May 5;281(17):1598-604. doi: 10.1001/jama.281.17.1598. JAMA. 1999. PMID: 10235152

7

Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer.

Fowler FJ Jr, McNaughton Collins M, Albertsen PC, Zietman A, Elliott DB, Barry MJ. Fowler FJ Jr, et al. Among authors: zietman a. JAMA. 2000 Jun 28;283(24):3217-22. doi: 10.1001/jama.283.24.3217. JAMA. 2000. PMID: 10866869

8

Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy.

Zietman AL, Thakral H, Wilson L, Schellhammer P. Zietman AL, et al. J Urol. 2001 Nov;166(5):1702-6. J Urol. 2001. PMID: 11586206

9

Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors.

Chawla AK, Thakral HK, Zietman AL, Shipley WU. Chawla AK, et al. Urology. 2002 May;59(5):726-31. doi: 10.1016/s0090-4295(02)01540-6. Urology. 2002. PMID: 11992848

10

United States radiation oncologists' and urologists' opinions about screening and treatment of prostate cancer vary by region.

McNaughton Collins M, Barry MJ, Zietman A, Albertsen PC, Talcott JA, Walker Corkery E, Elliott DB, Fowler FJ Jr. McNaughton Collins M, et al. Among authors: zietman a. Urology. 2002 Oct;60(4):628-33. doi: 10.1016/s0090-4295(02)01832-0. Urology. 2002. PMID: 12385923

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

377 results

Search Page

Filters